These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 29858218)

  • 61. Sipuleucel-T: a therapeutic cancer vaccine for the treatment of castration- or hormone-refractory prostate cancer.
    Bulloch MN; Elayan MM; Renfroe HR
    Expert Rev Clin Pharmacol; 2011 Nov; 4(6):685-92. PubMed ID: 22111853
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.
    Gardner TA; Elzey BD; Hahn NM
    Hum Vaccin Immunother; 2012 Apr; 8(4):534-9. PubMed ID: 22832254
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions.
    Handy CE; Antonarakis ES
    Future Oncol; 2018 Apr; 14(10):907-917. PubMed ID: 29260582
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy.
    Bilen MA; Hess KR; Subudhi SK; Aparicio A; Kim J; Zurita-Saavedra AJ; Araujo JC; Corn PG; Stover J; Lin SH; Logothetis CJ; Tu SM
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):583-589. PubMed ID: 28730293
    [TBL] [Abstract][Full Text] [Related]  

  • 65. CD54 is a surrogate marker of antigen presenting cell activation.
    Sheikh NA; Jones LA
    Cancer Immunol Immunother; 2008 Sep; 57(9):1381-90. PubMed ID: 18297282
    [TBL] [Abstract][Full Text] [Related]  

  • 66. An overview of sipuleucel-T: autologous cellular immunotherapy for prostate cancer.
    Wesley JD; Whitmore J; Trager J; Sheikh N
    Hum Vaccin Immunother; 2012 Apr; 8(4):520-7. PubMed ID: 22370520
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide.
    Peshwa MV; Shi JD; Ruegg C; Laus R; van Schooten WC
    Prostate; 1998 Jul; 36(2):129-38. PubMed ID: 9655265
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
    Small EJ; Fratesi P; Reese DM; Strang G; Laus R; Peshwa MV; Valone FH
    J Clin Oncol; 2000 Dec; 18(23):3894-903. PubMed ID: 11099318
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer.
    McNeel DG; Nguyen LD; Ellis WJ; Higano CS; Lange PH; Disis ML
    Prostate; 2001 May; 47(3):222-9. PubMed ID: 11351352
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Combination of p53-DC vaccine and rAd-p53 gene therapy induced CTLs cytotoxic against p53-deleted human prostate cancer cells in vitro.
    Saito H; Kitagawa K; Yoneda T; Fukui Y; Fujsawa M; Bautista D; Shirakawa T
    Cancer Gene Ther; 2017 Jul; 24(7):289-296. PubMed ID: 28621316
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
    Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ;
    Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
    Dawson NA; Roesch EE
    Expert Opin Biol Ther; 2014 May; 14(5):709-19. PubMed ID: 24620782
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The evolving role of immunotherapy in prostate cancer.
    Gerritsen WR
    Ann Oncol; 2012 Sep; 23 Suppl 8():viii22-7. PubMed ID: 22918924
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Immunotherapy for castration-resistant prostate cancer.
    Sonpavde G; Kantoff PW
    Urol Clin North Am; 2012 Nov; 39(4):465-81. PubMed ID: 23084524
    [TBL] [Abstract][Full Text] [Related]  

  • 75. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer.
    Becker JT; Olson BM; Johnson LE; Davies JG; Dunphy EJ; McNeel DG
    J Immunother; 2010; 33(6):639-47. PubMed ID: 20551832
    [TBL] [Abstract][Full Text] [Related]  

  • 76. High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance.
    Saeed MA; Peng B; Kim K; Rawat K; Kuehm LM; Siegel ZR; Borkowski A; Habib N; Van Tine B; Sheikh N; Tuyen V; Thorek DLJ; Fehniger TA; Pachynski RK
    Cancer Immunol Res; 2024 May; 12(5):559-574. PubMed ID: 38407894
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.
    Davis K; Wood S; Dill E; Fesko Y; Bitting RL; Harrison MR; Armstrong AJ; Moul JW; George DJ
    Clin J Oncol Nurs; 2015 Jun; 19(3):297-303. PubMed ID: 26000580
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A Mutated Prostatic Acid Phosphatase (PAP) Peptide-Based Vaccine Induces PAP-Specific CD8
    Vu PL; Vadakekolathu J; Idri S; Nicholls H; Cavaignac M; Reeder S; Khan MA; Christensen D; Pockley AG; McArdle SE
    Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454873
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Immune response to sipuleucel-T in prostate cancer.
    Thara E; Dorff TB; Averia-Suboc M; Luther M; Reed ME; Pinski JK; Quinn DI
    Cancers (Basel); 2012 Apr; 4(2):420-41. PubMed ID: 24213318
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.